It is relevant to point up that the use of the intensive follow-u

It is relevant to point up that the use of the intensive follow-up is still present in almost 45% of new generation RCTs. A possible limit of

our study may be represented by the choice of studies written in English, although the vast NVP-BSK805 majority of RCTs are currently published in this language and in scientific journal indexed in PubMed. In addition, it should be underlined that it is likely the statistic analysis could be not completely reliable, considering that in some of the subcategories considered in the study, the number of eligible RCTs is low. Conclusions Current breast cancer follow-up guidelines, which are based on RCTs, suggest a minimal follow-up approach for surveillance of early breast cancer patients, but this suggestion is not widely applied neither in phase III RCTs of adjuvant treatments nor in real world clinical practice. Whether the minimal follow-up approach will still be the recommended option in the future, is to be confirmed. In fact,

more effective and sophisticated diagnostic procedures may be useful to point out severe long-term side Torin 1 manufacturer effects of new molecularly targeted agents as well as an early detection of oligometastatic disease might be suitable for cure with newer therapeutic strategies, as it has been suggested for other neoplasms [143]. Finally, it would be highly desirable that in the near future the follow-up procedures will be homogeneous in RCTs and everyday clinical settings. Acknowledgments

Supported by the Pyruvate dehydrogenase Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). The authors are this website grateful to Mrs. Camille St. Pierre for careful reviewing of the manuscript. References 1. De Angelis R, Tavilla A, Verdecchia A, Scoppa S, Hachey M, Feuer EJ, Mariotto AB: Breast cancer survivors in the United States: geographic variability and time trends, 2005–2015. Cancer 2009,115(9):1954–1966.PubMed 2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013,63(1):11–30.PubMed 3. Piscitelli P, Barba M, Crespi M, Di Maio M, Santoriello A, D’Aiuto M, Fucito A, Losco A, Pentimalli F, Maranta P, et al.: The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records. J Exp Clin Cancer Res 2012, 31:96–104.PubMed 4. Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J, Todorovic V, Borojevic N, Croitoru A: Cancer epidemiology in Central, South and Eastern European countries. Croat Med J 2011,52(4):478–487.PubMed 5. Australian Institute of Health and Welfare: Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac J Clin Oncol 2013,9(3):199–213. 6. van Hezewijk M, Hille ET, Scholten AN, Marijnen CA, Stiggelbout AM, van de Velde CJ: Professionals’ opinion on follow-up in breast cancer patients; perceived purpose and influence of patients’ risk factors.

Comments are closed.